Allergan reports $1.206 billion in total net sales for fourth quarter

IRVINE, Calif. - Allergan reported a 15.9% increase in total product net sales for the fourth quarter of 2009 compared with the fourth quarter of 2008, the company announced in a press release.

Total product net sales were $1.206 billion, up from $1.041 billion in the fourth quarter of 2008. Adjusted for constant currency valuation, the increase was 11.2%, according to the release.

Total specialty pharmaceutical net sales increased 17.7%, or 13.1% on a constant currency basis, compared with the fourth quarter of 2008. Unaudited eye care pharmaceutical sales totaled $565.9 million, an increase of $99 million from the fourth quarter of 2008.

Total medical device net sales rose 8.3%, or 3.1% on a constant currency basis, the release said.

Non-GAAP diluted earnings per share attributable to stockholders was $0.78 in the fourth quarter of 2009, an increase of 2.6% compared with the fourth quarter of 2008.

Product net sales are expected to total $4.55 billion to $4.75 billion for the full-year 2010 and $1.06 billion to $1.1 billion in the first quarter of 2010. For the full year, sales of Alphagan (brimonidine tartrate ophthalmic solution) are expected to total $320 million to $340 million. Restasis (cyclosporine ophthalmic emulsion 0.05%) is expected to generate $580 million to $600 million.

Specialty pharmaceutical net sales are expected to be between $3.78 billion and $3.93 billion. Medical device net sales are expected to total between $770 million and $820 million.

Follow OSNSuperSite.com on Twitter.